Skip to main content

Neurocrine Bioscienc(NBIX-Q)
NASDAQ

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time

Neurocrine Biosciences Reports Fourth Quarter and Fiscal 2022 Financial Results and Provides Financial Expectations for 2023

PR Newswire - Mon Feb 6, 2023

INGREZZA® (valbenazine) Fourth Quarter Net Product Sales of $399 Million

INGREZZA® (valbenazine) 2023 Net Product Sales Guidance of $1.67 - $1.77 Billion

Read more at prnewswire.com

Provided Content: Content provided by PR Newswire. The Globe and Mail was not involved, and material was not reviewed prior to publication.

More from The Globe